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Calcium dysregulation contributes 
to neurodegeneration in FTLD 
patient iPSC-derived neurons
Keiko Imamura1, Naruhiko Sahara2, Nicholas M. Kanaan3, Kayoko Tsukita1, Takayuki Kondo1, 
Yumiko Kutoku4, Yutaka Ohsawa4, Yoshihide Sunada4, Koichi Kawakami5, Akitsu Hotta1, 
Satoshi Yawata6, Dai Watanabe6, Masato Hasegawa7, John Q. Trojanowski8, Virginia M.-Y. Lee8,  
Tetsuya Suhara2, Makoto Higuchi2 & Haruhisa Inoue1
Mutations in the gene MAPT encoding tau, a microtubules-associated protein, cause a subtype of 
familial neurodegenerative disorder, known as frontotemporal lobar degeneration tauopathy (FTLD-
Tau), which presents with dementia and is characterized by atrophy in the frontal and temporal lobes 
of the brain. Although induced pluripotent stem cell (iPSC) technology has facilitated the investigation 
of phenotypes of FTLD-Tau patient neuronal cells in vitro, it remains unclear how FTLD-Tau patient 
neurons degenerate. Here, we established neuronal models of FTLD-Tau by Neurogenin2-induced 
direct neuronal differentiation from FTLD-Tau patient iPSCs. We found that FTLD-Tau neurons, either 
with an intronic MAPT mutation or with an exonic mutation, developed accumulation and extracellular 
release of misfolded tau followed by neuronal death, which we confirmed by correction of the intronic 
mutation with CRISPR/Cas9. FTLD-Tau neurons showed dysregulation of the augmentation of Ca2+ 
transients evoked by electrical stimulation. Chemogenetic or pharmacological control of neuronal 
activity-relevant Ca2+ influx by the introduction of designer receptors exclusively activated by designer 
drugs (DREADDs) or by the treatment with glutamate receptor blockers attenuated misfolded 
tau accumulation and neuronal death. These data suggest that neuronal activity may regulate 
neurodegeneration in tauopathy. This FTLD-Tau model provides mechanistic insights into tauopathy 
pathogenesis and potential avenues for treatments.
Late-onset neurodegenerative diseases are becoming a growing burden to society due to the gradual increase in 
life expectancy and dramatic rise in prevalence of these diseases. Accumulating evidence strongly implicates mis-
folded proteins as a causative agent for most neurodegenerative diseases1–5 including neurodegenerative tauopa-
thies6–10, which are diseases associated with the pathological aggregation of microtubule-associated protein tau 
in the brain. Mutations in tau gene (MAPT) cause a familial disease known as frontotemporal lobar degeneration 
tauopathy or FTLD-Tau, which presents with dementia and is characterized by prominent atrophy in the frontal 
and temporal lobes of the human brain.
Tau is axonal microtubule-associated protein that contributes to the stabilization of microtubules. There are 
six tau isoforms, the result of the splicing of exons 2, 3 and 10. Alternative splicing of exon 10, which encodes the 
microtubule-binding domains (MBDs), generates 3-repeat tau with 3 MBDs or 4-repeat tau with 4 MBDs. Exonic 
mutations in MAPT are known to attenuate the ability of tau to bind to microtubules, accelerate self-aggregation, and 
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alter MAPT splicing11–13. Intronic mutations in MAPT are shown to affect exon 10 splicing and increase 4 repeat 
tau, which is accumulated in postmortem brain of patients with an intronic mutation14,15.
Although the developments in induced pluripotent stem cell (iPSC) technology have facilitated the investigation 
of phenotypes of neurodegenerative diseases including FTLD-Tau patient neural cells in vitro16–19, the mechanism 
involved in neurodegeneration in FTLD-Tau patient neurons is still unclear. Here, we established an FTLD-Tau 
iPSC model using Neurogenin2 (Ngn2)-induced direct neuronal differentiation from FTLD-Tau patients 
Figure 1. Generation of iPSCs from FTLD-Tau patients with either intronic or exonic MAPT mutation 
and gene editing for isogenic control. (a) iPSCs generated from familial FTLD-Tau patients with a MAPT 
mutation showed ESCs-like morphology (phase image) and expressed the pluripotent stem cell markers 
SSEA4 and Nanog. Scale bar = 100 μ m. (b) The FTLD-Tau1 iPSC line carried a MAPT intron mutation (intron 
10 + 14C → T), and the FTLD-Tau2 iPSC line carried a MAPT exon mutation (R406W). (c,d) The mutation in 
FTLD-Tau1 was corrected (FTLD-Tau1 corrected) using the CRISPR/Cas9 system. Sanger sequence analysis 
revealed correction of the mutation after gene editing. (e) RT-PCR showing FTLD-Tau1 neurons with increased 
4 repeat tau expression, and FTLD-Tau1 corrected neurons with the normal expression ratio of 4 repeat and 
3 repeat tau. Full-length picture of the gel is presented in Figure S4(a). (f) Cell lysates were dephosphorylated 
with lambda phosphatase and separated by SDS-PAGE for comparison with recombinant tau ladder followed by 
detection using an anti-total tau antibody (Tau12). Altered band pattern of FTLD-Tau1 was reversed in FTLD-
Tau1 corrected. Full-length picture of the blot is presented in Figure S4(b).
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Figure 2. Accumulation of misfolded tau in FTLD-Tau neurons. (a) An experimental time line for FTLD-Tau 
modeling. (b) Western blot analysis showing total tau, MAP2A/B, and β III tubulin in generated neurons. There 
were no significant differences in MAP2A/B levels among the neuronal lines, indicating no significant difference 
of neuronal differentiation. Full-length pictures of the blots are presented in Figure S4(c–f). (c) Intracellular 
misfolded tau accumulation in FTLD-Tau neurons (green, β III tubulin-positive cells) was detected by TOC1 
antibody (red) with a punctate pattern. Scale bar = 10 μ m. (d,e) Dot blot analysis of FTLD-Tau neurons. The 
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either with an intronic or with an exonic MAPT mutation20. This direct conversion method produces a robust 
amount of cortical neurons. We also generated an isogenic control iPSCs by the clustered regularly interspaced 
short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system, and observed accumulation 
and extracellular release of misfolded tau protein followed by neuronal death resulting in the recapitulation of 
the converged phenotypes of MAPT intronic and exonic mutations. Furthermore, to explore the mechanism of 
neurodegeneration in FTLD-Tau, we generated FTLD-Tau iPSCs constitutively expressing designer receptors 
exclusively activated by designer drugs (DREADDs), and found that calcium dysregulation contributed to the 
neurodegeneration.
Results
We generated iPSCs from FTLD-Tau patients with a mutation, either intron 10 + 14C → T14, or exon R406W21 
(Figs 1(a,b) and S1(a,b) and Table S1). These patients presented frontotemporal dementia. The intron 
10 + 14C → T mutation was corrected using CRISPR/Cas9 (Fig. 1(c,d)). Ngn2 was introduced into these iPSCs 
via a piggyBac vector with a tet-on expression system, followed by drug selection for stable-line establishment. 
The established iPSCs were converted to cortical neurons after 7 days of culture in neuronal medium with dox-
ycycline. There were no differences in the differentiation propensities of the resulting lines; the percentages of 
neurons in control, FTLD-Tau1, FTLD-Tau1 corrected, and FTLD-Tau2 lines were 89.5 ± 1.9%, 91.2 ± 0.9%, 
90.6 ± 1.6%, and 87.6 ± 0.2%, respectively (n = 3). The generated neurons expressed mRNA of receptors of neu-
rotransmitters (Figure S1(c)), and electrophysiological analysis presented their functional properties (Figure 
S2(a–h)). FTLD-Tau1 neurons with the intron 10 mutation showed increased 4-repeat tau expression compared 
with the 3-repeat tau expression, as previously reported14, and correction of the mutation repaired the ratio 
(Fig. 1(e,f)). We modeled FTLD-Tau using these FTLD-Tau and control neurons (Fig. 2(a)). The differentiated 
neurons exhibited neuron marker MAP2A/B, and these levels were not different between the respective lines 
(Fig. 2(b)). FTLD-Tau neurons, both with the intronic MAPT mutation and with the exonic mutation harbored 
accumulations of intracellular misfolded tau detected by immunocytochemistry using an anti-oligomeric aggre-
gate antibody, TOC1 antibody22,23 (Figs 2(c) and S3(a) and Table S2). Some FTLD-Tau neurons exhibited typical 
misfolded tau puncta and dots, and control neurons including the gene-corrected line were mostly negative for 
misfolded tau puncta or dots. Dot blot analysis presented accumulation of intracellular misfolded form of tau in 
non-denaturing condition using TOC1 antibody (Fig. 2(d,e)). We also analyzed misfolded tau by western blot 
analysis using TOC1 antibody to detect tau species in a denaturing condition as shown previously23. FTLD-Tau 
neurons either with the intronic MAPT mutation or the exonic mutation exhibited accumulations of tau species 
with higher molecular weight than control (Fig. 2(f)). However, there was a difference in molecular weight shift-
ing of misfolded tau between FTLD-Tau neurons with the intronic MAPT mutation and with the exonic mutation 
(Fig. 2(f)), suggesting that conformation of misfolded tau might not be uniform in the denaturing condition. 
Furthermore, FTLD-Tau neurons presented misfolded tau release into culture medium as detected by dot blot 
analysis (Fig. 2(g,h)) and confirmed by ELISA (Fig. 2(i)).
Neurons of FTLD-Tau model mice overexpressing human mutant tau24 and FTLD-Tau patients25 can show 
increased excitability. Furthermore, misfolded tau-exposed neurons exhibited increased intracellular Ca2+ lev-
els26. Thus, we evaluated Ca2+ transient of FTLD-Tau neurons by calcium imaging assay. Electrical stimulations 
increased intracellular Ca2+ levels, and the increased ratio was greater in FTLD-Tau neurons compared with 
control neurons, indicating increased excitability of FTLD-Tau neurons (Fig. 3(a,b)). Next, we investigated the 
vulnerability of FTLD-Tau neurons to degeneration, and found that they were more vulnerable to undergoing cell 
death than control neurons (Figs 3(c,d) and S3(b,c)).
We assessed the mechanistic links between the excitation of neurons and misfolded tau using DREADDs, 
which enabled us to control neuronal activity. We incorporated DREADDs, consisting of human muscarinic 
acetylcholine M4 receptor (M4D)27 bearing artificial mutations, into FTLD-Tau iPSCs using tol2 vectors fol-
lowing drug selection, and generated neurons constitutively expressing M4D (Fig. 4(a)). Stimulation of M4D 
by its exclusive agonist, clozapine-N-oxide (CNO), which inhibits calcium influx via Gi signaling, decreased 
intracellular and extracellular misfolded tau (Fig. 4(b–d)), suggesting that neuronal activity may modulate tau 
pathology. Furthermore, inhibition of Ca2+ influx by the N-methyl-D-aspartate (NMDA) receptor inhibitor 
D-2-amino-5-phosphonopentanoate (AP-5) and the α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptor inhibitor 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) increased survival of FTLD-Tau 
neurons (Fig. 4(e,f)).
Collectively, the cellular phenotypes of FTLD-Tau neurons, including accumulation of misfolded tau and neu-
ronal death, are similar for both the intronic and exonic MAPT mutations, and neuronal activity-relevant Ca2+ 
influx modulates neurodegeneration in tauopathy (Fig. 4(g)).
ratios of misfolded tau/total tau were increased in cell lysates of FTLD-Tau neurons (n = 3; one way ANOVA, 
p < 0.05; post hoc test, *p < 0.05). (f) Western blot analysis using TOC1 antibody under non-reducing condition 
showing misfolded high molecular tau in cell lysates of FTLD-Tau neurons. Full-length pictures of the blots 
are presented in Figure S4(g,h). (g,h) Dot blot analysis of FTLD-Tau neurons. The ratios of misfolded tau/total 
tau were increased in culture medium of FTLD-Tau neurons (n = 3; one way ANOVA, p < 0.05; post hoc test, 
*p < 0.05). (i) Misfolded tau in the culture medium supernatant was quantified by ELISA using TOC1 antibody 
for capture and anti-human tau antibody for detection. The level of misfolded tau was increased in culture 
medium of FTLD-Tau neurons (n = 3; one-way ANOVA, p < 0.05; post hoc test, *p < 0.05).
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Discussion
In the current study, we modeled FTLD-Tau using patients’ cortical neurons that exhibit an accumulation and 
extracellular release of misfolded tau and neuronal death, key findings of neurodegeneration due to tauopathy. 
These phenotypes were modulated by chemogenetic control of the introduced DREADDs or by glutamate recep-
tor blockers. Our findings suggest that neurodegeneration in FTLD-Tau involves misfolded tau and it is modu-
lated by neuronal activity.
We used iPSCs from two FTLD-Tau patients either with intronic mutation 10 + 14C → T or with exonic muta-
tion R406W. R406W mutation is reported to reduce the binding of tau to microtubules and promote formation 
of misfolded tau in model mice28. Mutation of intron 10 is known to affect exon 10 splicing and increase the 
ratio of 4R tau/3R tau. Imbalances in 4R and 3R tau are believed to cause neurodegeneration, but the pathogenic 
mechanisms were not well known, although model mice with overexpression of the intronic mutation showed 
neurodegeneration29. We found accumulation of misfolded tau in FTLD-Tau neurons with an intron mutation to 
be the same as with exon mutation. Since self-aggregation of 4R tau30,31 may be associated with the accumulation 
of misfolded tau in the intronic mutation, the accumulation of misfolded tau could be a converged feature in 
FTLD-Tau pathology in different MAPT mutations.
We found that the progressive accumulation and extracellular release of misfolded tau and these phenotypes 
were inhibited by DREADDs in FTLD-Tau neurons, which was supported by previous reports showing that 
tau oligomers, an intermediate in the early stages of tau misfolding before overt fibrillization, cause increased 
intracellular calcium levels24,25 and neuronal death of healthy neurons26. Since DREADDs regulate calcium influx 
associated with neuronal activity27, intracellular calcium influx may contribute to tau misfolding, as reported in 
other neurodegenerative disease-associated pathogenic proteins32, and extracellular release of misfolded tau may 
accelerate inter-neuronal propagation of tau.
In this study, we detected severe cell death of FTLD-Tau neurons. We speculated that, compared to conven-
tional differentiation method, transdifferentiation by introduction of transcription factor is likely a more stressful 
Figure 3. Calcium dysregulation and neuronal loss of FTLD-Tau neurons. (a,b) Calcium imaging after 
electrical stimulation. Intracellular Ca2+ levels, elevated by electrical stimulation, were higher in FTLD-Tau 
neurons than in control (n = 6; one-way ANOVA, p < 0.05; post hoc test, *p < 0.05). (c,d) Immunofluorescence 
staining of βIII tubulin and NeuN on Days 8 and 21 in control and FTLD-Tau neurons. Survival of FTLD-Tau 
neurons from Day 8 to Day 21 was decreased compared to control neurons (n = 6; one-way ANOVA, p < 0.05; 
post hoc test, *p < 0.05).
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process that may enhance some cellular phenotypes, or that a lack of support from glia cells may have enhanced 
the vulnerability of FTLD-Tau neurons in the present model. We consider that neurons need to reach functional 
maturity in order for mutant tau to be toxic. Although the neurons in the present study were at a very early dif-
ferentiation stage, these neurons exhibited glutamate receptor expression and functional property as shown by 
neurophysiological evaluation. Further investigation may be required to determine the precise neuronal function 
that allows mutant tau to be toxic.
Figure 4. Attenuation of neurodegeneration by regulation of Ca2+ influx. (a) Schema of Designer Receptor 
Exclusively Activated by Designer Drug (DREADD) systems for regulating neuronal activity. (b) Western blot 
analysis of misfolded tau in FTLD-Tau neurons after SDS-PAGE under non-reducing conditions using TOC1 
antibody. Stimulation of M4D neurons with CNO decreased the level of misfolded tau in cell lysates. Full-length 
pictures of the blots are presented in Figure S4(i,j). (c,d) Dot blot analysis of misfolded tau (TOC1) and total 
tau (Tau12) in FTLD-Tau neuron culture medium. Stimulation of M4D neurons with CNO decreased the level 
of extracellular misfolded tau (n = 3; Student-t test, *p < 0.05). (e) Treatment with AP-5 or CNQX increased 
survival of FTLD-Tau1 neurons. (n = 6; one-way ANOVA, p < 0.05; post hoc test, *p < 0.05). Bar graphs 
represent mean ± SEM. (f) Treatment with AP-5 or CNQX increased survival of FTLD-Tau2 neurons. (n = 6; 
one-way ANOVA, p < 0.05; post hoc test, *p < 0.05). Bar graphs represent mean ± SEM. (g) Summary of our 
findings.
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These results suggested that FTLD-Tau patient iPSCs would be useful for investigating and understanding 
converging mechanism underlying tau mediated neurodegeneration due to different MAPT mutations, and a 
designer iPSC model with DREADDs to control neural activity is likely an approach that could be applied to other 
neurodegenerative diseases.
Materials and Methods
Ethics statement. Generation and use of human iPSC was approved by the Ethics Committee of the 
Department of Medicine and Graduate School of Medicine, Kyoto University, and Kawasaki Medical School. All 
methods were performed in accordance with the approved guidelines. Formal informed consent was obtained 
from all subjects.
Generation of iPSCs and cell culture. Human iPSCs with a MAPT mutation were generated from fibro-
blasts or peripheral blood mononuclear cells (PBMCs) using episomal vectors for OCT3/4, Sox2, Klf4, L-Myc, 
Lin28, and dominant negative p53, as previously reported33, and were cultured on an SNL feeder layer with human 
iPSC medium (primate embryonic stem cell medium; ReproCELL, Yokohama, Japan) supplemented with 4 ng/ml 
basic FGF (Wako Chemicals, Osaka, Japan) and penicillin/streptomycin. As a control we used the 201B7 iPSC line34.
Generation of isogenic human FTLD-Tau iPSC lines with CRISPR/Cas9 gene editing technology. For 
targeting MAPT by CRISPR/Cas9, we designed a guide RNA to target the 5′ -GCAACGTCCAGTCCAAGTGTGG-3′ 
site using CRISPR Design (http://crispr.mit.edu/). The guide RNA oligonucleotide was inserted into the 
BamHI-EcoRI site in pHL-H1-ccdB plasmids to express the insert under the control of human H1 polymerase III 
promotor35. We inserted 5′ and 3′ homology arms with normal MAPT sequence, and puromycin-resistant cassette 
flanked with piggyBac terminal repeat into pBluescript SK(+ ) to construct the donor plasmid. For transfection of 
CRISPR/Cas9, one million iPSCs were electroporated with 10 μ g of pHL-Hi guide RNA expression plasmids, 10 μ g 
of pHL-EF1a-hcSpCas9 plasmids, and 10 μ g of donor plasmids by NEPA21 electroporator (Nepagene, Chiba, Japan). At 
4 days post-transfection, puromycin selection was performed for 10 days. The puromycin-resistant colonies were cho-
sen and expanded for genomic DNA extraction and genotyping by PCR using the following primers: forward primer, 
5′ -AAATGCAGTCGTGGGAGACC-3′ ; reverse primer, 5′ -GAGTCCCGAATCTCACGGAGACA-3′. All ampli-
fied PCR bands were further analyzed by Sanger sequencing to confirm that there were no sequence alterations at the 
homology arms. To remove the puromycin cassete, the transposase vector pHL-EF1α -hcPBase36 was electroporated 
into the targeted clones, and successful removal of the puromycin cassette was confirmed by PCR: forward primer, 
5′ -AAATGCAGTCGTGGGAGACC-3′ ; reverse primer, 5′ -GAGTCCCGAATCTCACGGAGACA-3′ . To exclude the 
possibility of re-integration of the puromycin-resistance cassette, we performed PCR of the puromycin cassette and con-
firmed its non-integration with the following primers: forward primer, 5′ -CTGCTGCAACTTACCTCCGGGATG-3′ ; 
reverse primer, 5′ -CCAATCCTCCCCCTTGCTGTCCTG-3′ .
Preparation of a piggyBac vector for expressing Ngn2 and introduction into iPSCs. To robustly 
generate homogenous neurons from iPSCs, we introduced the Ngn2 transcription factor into iPSCs using a piggy-
Bac vector. This vector, containing Ngn2 under control of the tetracycline operator rtTA and neomycin resistance 
gene, was generated from the KW110_PB_TA_ERN (Ef1a_rtTA_neo) vector backbone37. The generated vector 
was then co-transfected together with a pCyL43 vector encoding transposase into iPSCs using lipofectamin LTX 
(Thermo Fisher Scientific, Waltham, MA). After clone selection using neomycin, we established iPSCs carrying 
the tetracycline-inducible Ngn2 construct.
Generation of cortical neurons from iPSCs via induction of Ngn2. iPSCs were dissociated to single 
cells using acutase and plated on Matrigel-coated plastic plates or cover slips with the neural medium containing 
a 1:1 ratio of DMEM/F12 (Thermo Fisher Scientific) and Neurobasal (Thermo Fisher Scientific), 1% N2 supple-
ment, 2% B27 supplement, 10 ng/ml brain-derived neurotrophic factor (BDNF, R&D Systems), 10 ng/ml glial 
cell-derived neurotrophic factor (GDNF, R&D Systems, Minneapolis, MN) and 10 ng/ml neurotrophin-3 (NT-3; 
R&D Systems) with 1 μ g/ml doxycycline (TAKARA, Kusatsu, Japan).
Introduction of DREADDs and analysis of misfolded tau after chemical stimulation for DREADDs. 
The designer receptor exclusively activated by designer drug (DREADD) technique was used to control neuronal 
activity. We introduced a human M4 muscarinic DREADD (M4D) into iPSCs using a tol2 vector38. A tol2 vector 
containing M4D under control of the CAG promoter and hygromycine resistance gene was generated from the 
pT2AL200R175-CAGGS-EGFP vector backbone following removal of the EGFP gene38. The generated vector 
was co-transfected along with a vector encoding transposase into the Ngn2-introduced iPSCs using lipofectamin 
LTX. After clone selection using hygromycin, we established iPSC lines carrying M4D. After the generated iPSCs 
were differentiated into neurons with doxycycline and neural medium for 8 days, the pharmacologically inert, 
designer drug clozapine-N-oxide (CNO) of 100 nM was added to culture medium to stimulate DREADD. On 
Day14, western blot analysis and dot blot analysis were performed.
Reverse transcriptase PCR. Total RNA of cultured cells was extracted using an RNeasy Plus Mini kit (QIAGEN, 
Hilden, Germany). One microgram of RNA was reverse-transcribed using ReverTra Ace (TOYOBO, Osaka, Japan). 
PCR analysis was performed with TAKARA Ex Taq (TAKARA). Primer sets for 3 repeat tau and 4 repeat tau 
were used as previously reported; forward 5′ -AAGTCGCCGTCTTCCGCCAAG-3′ ; reverse 5′ -GTCCAGGG 
ACCCAATCTTCGA-3′ . RT-PCR products were evaluated on 3% agarose gel: RT-PCR products of 3 repeat tau 
and 4 repeat tau were 288 and 381 bp, respectively17.
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Quantitative RT-PCR. Total RNA of cultured cells on Day 7 was extracted using an RNeasy Plus Mini kit 
(QIAGEN). One microgram of RNA was reverse-transcribed using ReverTra Ace (TOYOBO). Quantitative PCR 
analysis was performed by reverse transcription reaction with SYBR Premix Ex TaqII (TAKARA) using Step One 
Plus (Applied Biosystems, Waltham, MA). Primer sets are listed in Table S3.
Immunocytochemistry. Cells were fixed in 4% paraformaldehyde for 30 min at room temperature, washed 
with PBS, and permeabilized in PBS containing 0.2% Triton X-100 for 10 min at room temperature, followed by 
blocking for 30 min with Block Ace (Yukijirushi, Tokyo, Japan). After incubation with primary antibodies over-
night at 4 °C, cells were washed three times with PBS and incubated with appropriate secondary antibodies for 
1 h at room temperature. Cell images were acquired with Delta Vision (GE Healthcare, Chicago, IL) or IN Cell 
Analyzer 6000 (GE Healthcare). The numbers of cells were quantified with IN Cell Analyzer 6000 and IN CELL 
Developer toolbox software 1.9 (GE Healthcare). The following primary antibodies were used in this assay: β 
III tubulin (1:2,000, Covance, Princeton, NJ), NeuN (1:500, Millipore, Darmstadt, Germany), TOC1 (1:1,000), 
Nanog (1:200, Abcam, Cambridge, UK), and SSEA4 (1:500, Millipore).
Western blot analysis. Cells were harvested and dissolved in RIPA buffer containing 0.1% SDS, 150 mM NaCl, 
1% NP-40, 0.5% deoxycholate, 50 mM Tris-HCl (pH8.0), protease inhibitor (Roche, Basel, Switzerland), and phos-
phatase inhibitor (Roche). After sonication, samples were centrifuged at 13,000 × g for 15 min at 4 °C. Protein concen-
trations in the supernatants were determined using the bicinchoninic acid (BCA) assay kit (Thermo Fisher Scientific). 
Total protein extracts (20 μ g per lane) with or without 2-mercaptoethanol, reducing condition or non-reducing 
condition, respectively, were separated by size on 10% polyacrylamide gels and transferred to an Immobilon-P 
membrane (Millipore). Membranes were blocked with 5% skim milk, hybridized with appropriate antibodies, and 
visualized using the ECL Prime detection kit (GE Healthcare). Images were acquired on ImageQuant LAS 4000 (GE 
Healthcare). The following primary antibodies were used: MAP2 (1:1,000, CST, Danvers, MA), β III tubulin (1:5,000, 
Covance), Tau12 (1:10,000, Millipore), TOC1 (1:5,000), and β -actin (1:5,000, SIGMA, St. Louis, MO).
It is noteworthy that a non-denaturing condition is required to assess the oligomeric form of tau using the 
TOC1 antibody, as this antibody has a linear epitope that is displayed in oligomers compared to monomers or 
filaments23. Using denaturing conditions does not allow for the distinction between these different tau species, 
oligomers, monomers, and/or filaments, using TOC1.
Dot blot analysis. Cells were harvested and lysed in TBS containing protease inhibitor and phosphatase 
inhibitor. After sonication and centrifugation at 13,000 × g for 15 min, each of the lysate samples (1.2 μ g/spot) 
was loaded on a nitrocellulose membrane (0.45 μ m pore size, GE Healthcare). Cell culture medium was collected 
and centrifuged at 800 × g for 3 min to remove debris. 500 μ l supernatant from each sample was concentrated to 
50 μ l using Vivaspin (GE Healthcare), with a molecular weight cut-off of the filtration membrane of 10 kD. 2 μ l 
of each concentrated sample was loaded on a nitrocellulose membrane. Membranes were blocked with 5% skim 
milk, hybridized with appropriate antibodies, and visualized using Western Lightning Plus-ECL (PerkinElmer, 
Waltham, MA). Images were acquired on ImageQuant LAS 4000 (GE Healthcare). The following primary anti-
bodies were used: Tau12 (1:10,000, Millipore) and TOC1 (1:5,000).
Cell survival assay. Ngn2-introduced iPSCs were dissociated to single cells, and 5 × 104 cells/well were 
plated on Matrigel-coated 96-well plates (BD Bioscience, Franklin Lakes, NJ) with neural medium containing 
1 μ g/ml doxycycline. Cells were fixed and stained on Days 8 and 21. The number of surviving neurons stained 
with NeuN was quantified by IN Cell Analyzer 6000 (GE Healthcare), and expressed as the number of neu-
rons on Day 21/Day 8. To inhibit neuronal activation, D-2-amino-5-phosphonopentanoate (AP-5) (SIGMA) 
and 6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX) (SIGMA) were added daily from Day 8 to Day 21, and the 
number of surviving neurons was evaluated on Day 21.
Cell death assay. Ngn2-introduced iPSCs were dissociated to single cells, and 5 × 104 cells/well were plated 
on Matrigel-coated 96-well plates (BD Bioscience) with neural medium containing 1 μ g/ml doxycycline. Culture 
medium was changed on day 8, and propidium iodide (PI) staining was performed on day 10. Cells were incu-
bated with 1.5μ M PI (NACALAI TESQUE, Kyoto, Japan) for 30 min at 37 °C, and fixed in 4% paraformaldehyde. 
The number of PI stained cells was quantified by IN Cell Analyzer 6000.
Enzyme-linked immunosorbent assay (ELISA) of misfolded tau. 96-well plates (Greiner, 
Frickenhausen, Germany) were coated with 3 μ g/ml TOC1 antibody in 0.05 M sodium carbonate buffer at 4 °C 
overnight. After washing and blocking with TBS-T containing 1% BSA, 100 μ l of cultured medium was added, 
and incubation was carried out for 2 h at room temperature. Recombinant oligomeric tau protein was used to 
obtain a standard curve. For detection, the plates were incubated with 2 μ g/ml affinity-purified rabbit polyclonal 
anti-human tau antibody, followed by sheep anti-rabbit IgG F(ab)’2 fragment linked to horseradish peroxidase 
(1:3,000; GE Healthcare). After incubation with tetramethylbenzidine solution (BD Bioscience) at room tem-
perature for 30 min, absorbance at 450 nm was measured by VersaMax (Molecular Devices, Sunnyvale, CA). The 
anti-human tau antibody was raised against tau amino-terminus polypeptide (amino acids 19–33, according to 
the longest human tau isoform) by immunization of two rabbits.
Calcium imaging assay. iPSCs were dissociated to single cells, and 5 × 104 cells/well were plated on 
Matrigel-coated 96-well plates with neuronal medium containing 1 μ g/ml doxycycline. On Day 10, electri-
cally stimulated intracellular Ca2+ mobilization was measured using e-FDSS/μ CELL (Hamamatsu Photonics, 
Hamamatsu, Japan)39. In brief, cells were incubated with 5 μ M Fluo-8/AM (AAT Bioquest, Sunnyvale, CA) and 
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0.01% Pluronic F-127 (SIGMA) in neuronal medium for 30 min at 37 °C. After washing with PBS, the medium 
was changed to phenol red-free Neurobasal medium (Thermo Fisher Scientific). Electrical stimulations (Voltage: 
20 V, Pulse width: 3 msec, Number: 50 times/stimulation, Frequency: 50 Hz) were delivered to each well of the 
96-well plates, and fluorescence changes (excitation and emission wavelengths, 480 and 540 nm, respectively), 
expressed as a percentage of fluorescence recorded before and after stimulation, were recorded.
Electrophysiological recordings. Whole-cell patch-clamp recordings were performed from iPSC-derived 
neurons. The recording micropipettes were filled with intracellular solution consisting of 140 mM KCl, 2 mM 
MgCl2, 10 mM HEPES, and 1 mM EGTA, adjusted to pH7.4 with NaOH. Cells were maintained at 30 °C dur-
ing the experiment and were continuously superfused with oxygenated Krebs-Ringer solution consisting of 
125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, and 20 mM glucose. 
Voltage-clamp and current-clamp recordings were made using an EPC9 amplifier (HEKA, Lambrecht, Germany), 
and data were analyzed with Patchmaster software (HEKA).
Statistical analysis. Results were analyzed using one-way ANOVA followed by Tukey post hoc analysis or 
student’s t-test to determine statistical significance. Differences were considered significant at p < 0.05. Analyses 
were performed using SPSS software (IBM, Armonk, NY). All bar graphs represent mean ± SEM.
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